Clinical Trials
3 trialsNCT02996825 2024-04-02
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03106077 2020-12-02
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03045393 2018-07-05
IMGN853
Duke University
Phase 1 Withdrawn